Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

Losing the FDA’s senior negotiators would slow the renewal of the user fee programs “considerably,” according to policy and ...

Industry representatives will still be allowed at these meetings, but they will no longer have a spot on the advisory ...